


Nanotechnology Based Approaches for Tuberculosis Treatment

Edited by Prashant Kesharwani



NANOTECHNOLOGY
BASED APPROACHES
FOR TUBERCULOSIS
TREATMENT

Page left intentionally blank

NANOTECHNOLOGY BASED APPROACHES FOR TUBERCULOSIS TREATMENT

Edited by

PRASHANT KESHARWANI

Assistant Professor & Ramanujan Fellow, Department of Pharmaceutics,

School of Pharmaceutical Education and Research

Jamia Hamdard (Hamdard University)

New Delhi, India



ACADEMIC PRESS

An imprint of Elsevier

Academic Press is an imprint of Elsevier
125 London Wall, London EC2Y 5AS, United Kingdom
525 B Street, Suite 1650, San Diego, CA 92101, United States
50 Hampshire Street, 5th Floor, Cambridge, MA 02139, United States
The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, United Kingdom

Copyright © 2020 Elsevier Inc. All rights reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions.

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

Notices

Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.

To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

Library of Congress Cataloging-in-Publication Data

A catalog record for this book is available from the Library of Congress

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library

ISBN: 978-0-12-819811-7

For information on all Academic Press publications
visit our website at <https://www.elsevier.com/books-and-journals>

Publisher: Andre Gerhard Wolff
Acquisitions Editor: Erin Hill-Parks
Editorial Project Manager: Pat Gonzalez
Production Project Manager: Maria Bernard
Designer: Miles Hitchen

Typeset by Thomson Digital



Contents

Contributors ix

Preface xi

1. Pathogenesis, biology, and immunology of tuberculosis 1

RAVI BANDARU, DEVIPRASAD SAHOO, RAMAKANTA NAIK,
PRASHANT KESHARWANI AND RAMBABU DANDELA

- 1 Introduction 1
 - 2 *Mycobacterium tuberculosis* and its transmission 2
 - 2.1 Scientific classification 2
 - 2.2 Transmission 2
 - 3 Factors responsible for its transmission 3
 - 3.1 Patient-related risk factor 3
 - 3.2 Bacteriological factors 4
 - 4 Pathogenesis 5
 - 4.1 Survival mechanisms of *Mycobacterium tuberculosis* 6
 - 5 *Mycobacterium tuberculosis* capsule 12
 - 5.1 Cellular structure of *Mycobacterium tuberculosis* capsule 12
 - 5.2 Host-pathogen interaction from the capsule point of view 12
 - 5.3 Pharmaceutical methodology to target capsule 14
 - 6 Immunology—Introduction 15
 - 6.1 Immunology of tuberculosis 15
 - 6.2 Innate immune system 16
 - 6.3 Inflammatory responses 20
 - 6.4 Adaptive immunity 21
 - 6.5 Granuloma formation 22
 - 6.6 Conclusion 23
- References 24

2. Tuberculosis: introduction, drug regimens, and multidrug-resistance 27

SIMA SINGH, NEELAM DHANKAR, ASHISH KUMAR GARG,
NAGASHEKHARA MOLUGULU AND PRASHANT KESHARWANI

- 1 Introduction 27
- 2 Drug regimens for the treatment of tuberculosis 28

- 3 First line drugs for tuberculosis 29
 - 4 Isoniazid 29
 - 5 Rifampin 30
 - 6 Pyrazinamide 30
 - 7 Ethambutol 30
 - 8 Streptomycin 31
 - 9 Second-line antituberculosis drugs 31
 - 10 Mechanisms of drug resistance 32
 - 11 Conclusions 33
- References 33

3. Nanotechnology as a potential tool against drug- and multidrug-resistant tuberculosis 37

DAMIÁN EDUARDO PÉREZ-MARTÍNEZ
AND ROBERTO ZENTENO-CUEVAS

- 1 Tuberculosis as an infectious disease 37
 - 2 Nanotechnology-based systems and the administration of drugs against tuberculosis 38
 - 2.1 Solid-lipid forms 40
 - 2.2 Emulsion-based systems 41
 - 2.3 Vesicular drug-delivery systems 41
 - 2.4 Miscellaneous NPs 43
 - 3 Factors affecting NPs properties 48
 - 3.1 Potential benefits and risks in the use of NPs 48
- References 49

4. Translational research for therapy against tuberculosis 53

YOLANDA GONZALEZ, SILVIA GUZMÁN-BELTRÁN,
LAURA E. CARRETO-BINAGHI AND ESMERALDA JUÁREZ

- 1 Research for tuberculosis elimination 53
- 2 Advances in the therapy for tuberculosis 55
- 3 New drugs for tuberculosis or new regimens 56
 - 3.1 The issues 56
 - 3.2 Recent advances 56
 - 3.3 Future challenges 58
- 4 Drugs repurposed for tuberculosis 58

4.1	The issues	58
4.2	Recent advances	58
4.3	Future challenges	60
5	Host-directed therapy for tuberculosis	61
5.1	The issues	61
5.2	Recent advances	61
5.3	Future challenges	62
6	Tuberculosis research and care biomarkers. The OMICs of tuberculosis	62
6.1	Genomics	63
6.2	Transcriptomics	64
6.3	Proteomics	65
6.4	Metabolomics	66
11	The impasse of translational medicine in tuberculosis and future challenges	66
	References	68

5. Vaccine delivery systems against tuberculosis 75

RUPAL OJHA, RAJAN KUMAR PANDEY
AND VIJAY KUMAR PRAJAPATI

1	Introduction	75
2	TB vaccine candidates in the pipeline	77
2.1	Viral vectored TB vaccines	78
2.2	Adjuvanted subunit TB vaccine	78
2.3	DNA TB vaccine	78
2.4	Whole-cell and live <i>Mycobacteria</i> TB vaccine	80
3	Vaccine administration routes for TB vaccine	80
3.1	Intradermal route of administration	81
3.2	The intramuscular route of administration	81
3.3	Subcutaneous route of administration	81
3.4	Intranasal (mucosal, sublingual) route of administration	81
4	Advanced TB vaccine delivery systems and their related immune responses	82
4.1	Nanoparticles-based TB vaccine delivery systems	82
4.2	Cationic nanoparticle-based TB vaccine delivery	83
4.3	Chitosan-based nanoparticle TB vaccine delivery	83
4.4	Polymeric/polyester-based nanoparticle as a TB vaccine delivery system	84
4.5	Liposome-based TB vaccine delivery	85

4.6	Dendrimer-based TB vaccine delivery system	85
4.7	Immune stimulating complexes (ISCOMs) as a TB vaccine delivery system	86
4.8	Virus-like particles (VLPs)-based TB vaccine delivery system	86
4.9	Virosomes-based TB vaccine delivery system	87
4.10	Role of adjuvants in TB vaccine formulation and their delivery	87
	References	88

6. Inhalable polymeric dry powders for antituberculosis drug delivery 91

SUNEERA ADLAKHA, KALPESH VAGHASIYA, ANKUR SHARMA,
EUPA RAY AND RAHUL KUMAR VERMA

1	Introduction	91
2	Challenges with current anti-TB therapies	92
3	Rationale of pulmonary drug delivery in TB	92
4	Feasibility of lung as a portal for delivery of ATD	93
5	Pulmonary delivery of ATD	94
6	Formulations for DPIs	96
7	Drug carriers for pulmonary delivery	96
7.1	Polymeric nanoparticles	96
7.2	Hybrid nano-in-microparticles	98
7.3	Solid-lipid nano particles	98
7.4	Liposomes	98
7.5	Microparticles	99
8	Inhalation delivery devices for DPI	99
9	Clinical trials	100
10	Future of polymeric powder-based drug development for TB	101
11	Conclusions	101
	References	102

7. Liposomes-and niosomes-based drug delivery systems for tuberculosis treatment 107

ALI IBRAHIM BEKRAKI

1	Introduction	107
2	Epidemiology	107
3	Nature of causative agent	108
4	Emergence of MDR and XDR TB	108
5	Drug regimens	109
6	Need for novel and sustained delivery systems	109
7	Nanodelivery systems	110
7.1	Introduction	110

- 7.2 Types of nanocarriers 110
- 7.3 Advantages of nanotechnology-based drug delivery system 110
- 8 Liposomes 111
- 8.1 Definition of liposomes 111
- 8.2 Types and uses of liposomes 111
- 8.3 Pulmonary TB and the importance of liposomal drugs 112
- 8.4 Si-RNA liposomes 113
- 8.5 Targeting of liposomes 114
- 9 Niosomes 115
- 9.1 Definition of niosomes 115
- 9.2 Advantages of niosomes 115
- 9.3 Various types of niosomes 116
- 9.4 Niosomes versus liposomes; which is superior? 116
- 9.5 Application of niosomes in drugs 116
- 9.6 Niosomes in the treatment of TB 117
- 9.7 Niosomal drug delivery system role in cerebral, drug-resistant TB 118
- 10 Pulmonary delivery of nanoparticle encapsulated antitubercular drugs 118
- 11 The future of combating TB 119
- References 120
8. Polymer-based nanoparticles as delivery systems for treatment and vaccination of tuberculosis 123
- MOHSEN TAFAGHODI, FARZAD KHADEMI, FARIDEH SHIEHZADEH AND ZOHREH FIROUZI
- 1 Polymer-based nanoparticles as drug delivery systems of tuberculosis 123
- 1.1 Nanocarriers based on natural polymers 124
- 1.2 Nanocarriers based on synthetic polymers 128
- 2 Nanoparticle-based delivery systems for vaccination against tuberculosis 130
- 2.1 Tuberculosis vaccines 130
- 2.2 Adjuvants 135
- 2.3 Vaccine delivery systems 136
- 2.4 The future challenges 139
- References 139
9. Nanotechnology-based approaches for tuberculosis treatment 143
- MOHAMAD MOSA MUBARAK AND ZAHOOR AHMAD
- 1 Drug delivery systems 143
- 2 Tuberculosis: the need for antitubercular drug delivery systems 144
- 3 Nanomedicine and tuberculosis 146
- 4 Oral ATD-nanomedicine 148
- 5 Ligand-appended oral ATD-nanomedicine 149
- 6 Pulmonary delivery of ATD-nanomedicine 150
- 7 Injectable ATD-nanomedicine 151
- 8 Alginate-based ATD-nanomedicine 151
- 9 Lipid-based ATD-nanomedicine 153
- 9.1 Liposome-based drug delivery systems 153
- 9.2 Microemulsions as potential ATD delivery systems 154
- 9.3 Niosomes-based ATD delivery system 155
- 9.4 Solid lipid nanoparticles-based ATD-nanomedicine 155
- 10 ATD-nanomedicine for special situations: cerebral TB, drug-resistant TB, and latent TB 156
- 11 Potential toxicity of ATD-nanomedicine 157
- 12 ATD-nanomedicine: unresolved and upcoming issues 157
- 13 Conflict of interest 158
- References 158
10. Dendrimer-based drug delivery systems for tuberculosis treatment 163
- RAHUL SHUKLA, AAKRITI SETHI, MAYANK HANDA, MRADUL MOHAN, PRASHANT KESHARWANI AND PUSHPENDRA K. TRIPATHI
- 1 Introduction 163
- 2 Dendrimers 165
- 3 PAMAM dendrimers for tuberculosis treatment 166
- 4 PPI dendrimers for tuberculosis treatment 168
- 5 Melamine, PEHAM, and PEA dendrimers for tuberculosis treatment 170
- 6 Conclusion 170
- References 171
11. Polymeric micelle-based drug delivery systems for tuberculosis treatment 175
- BAPI GORAIN, HIRA CHOUDHURY, SREENIVAS PATRO SISINTHY AND PRASHANT KESHARWANI
- 1 Introduction 175
- 2 The structure of polymeric micelle 176
- 2.1 Corona of miceller structure 176
- 2.2 Core of miceller structure 178

- 3 Commonly used polymers in polymeric micelle 179
 - 3.1 Commonly used amphiphilic block copolymers 179
 - 4 Polymeric micelles for enhanced permeability and retention effect 180
 - 4.1 Factors affecting EPR of micellar deliveries 182
 - 5 Tuberculosis and urge of novel delivery approaches 183
 - 6 Recent advances of polymeric micelles in tuberculosis 184
 - 7 Conclusion 185
- Conflict of interest 186
References 186

12. Nanostructured lipid carrier-based drug delivery systems for tuberculosis treatment 193

SIMONE PINTO CARNEIRO AND ORLANDO DAVID
HENRIQUE DOS SANTOS

- 1 Methods of production 196
 - 1.1 Hot homogenization method 196
 - 1.2 Cold homogenization method 196
 - 2 Excipients used in lipid nanocarriers 198
 - 2.1 Lipids 198
 - 2.2 Emulsifiers 198
 - 3 Challenges for current tuberculosis therapy 198
 - 4 Lipid nanoparticles for TB treatment 198
 - 5 Solid lipid nanoparticles and nanostructured lipid carriers as alternative nanomedicines for TB treatment 199
 - 6 Lipid nanoparticles functionalization 200
- References 202

13. DNA markers and nano-biosensing approaches for tuberculosis diagnosis 207

AMAL RABTI, AMAL RAOUAFI AND NOUREDDINE RAOUAFI

- 1 Introduction 208
- 2 DNA structure 208
- 3 Carbonaceous nanomaterials-based DNA biosensors 210
 - 3.1 Graphene derivatives 210
 - 3.2 Carbon nanotubes 213

- 4 Nanoparticles based-DNA biosensors 215
 - 4.1 Noble metal nanoparticles 215
 - 4.2 Metal oxide nanoparticles 222
 - 4.3 Magnetic beads 223
 - 4.4 Quantum dots 224
 - 5 Conclusion 226
- References 227

14. Recent advancement and future perspective for the treatment of multidrug-resistant tuberculosis 231

NOORSUZANA MOHD SHARIFF

- 1 Multidrug-resistant tuberculosis (MDR-TB): the emergence of new global threat to tuberculosis (TB) eradication 231
 - 2 The progression of treatment guidelines for MDR-TB: the past and present 233
 - 3 The advancement in MDR-TB treatment: the recent, on-going, and future direction 233
 - 3.1 The promising new all-oral drugs versus the extensively use injectable drugs 233
 - 3.2 Other ongoing trials for new treatment regimen for MDR-TB/XDR-TB 239
 - 4 Host-directed therapies as a future option in treating MDR-TB 240
 - 5 Conclusion 246
- References 246

15. Nanotechnology approach in conquering anti-TB resistance 251

BERNADETTE DIAN NOVITA

- 1 Mycobacterium: pathogenesis and its problem in the resistant 251
 - 2 Antituberculosis and the mechanism of antituberculosis resistant 253
 - 3 Nanoparticle and its use to conquer tuberculosis infection 258
 - 4 Function nanoparticle for overcoming resistance tuberculosis treatment 260
 - 5 Nanoparticle for diagnose tuberculosis 263
- References 266

Index 267

Contributors

Suneera Adlakha Institute of Nano Science and Technology (INST), Mohali, Punjab, India

Zahoor Ahmad Infectious Diseases PK/PD Lab, Life Science Block, Indian Institute of Integrative Medicine, Srinagar, Jammu and Kashmir, India

Ravi Bandaru Department of Industrial and Engineering Chemistry, Institute of Chemical Technology, Indianoil Odisha Campus, Bhubaneswar, India

Simone Pinto Carneiro Laboratory of Phytotechnology, School of Pharmacy, Federal University of Ouro Preto (UFOP), Ouro Preto, Minas Gerais, Brazil

Laura E. Carreto-Binaghi Department of Research in Microbiology, National Institute of Respiratory Diseases, Mexico City, Mexico

Hira Choudhury Department of Pharmaceutical Technology, School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia

Rambabu Dandela Department of Industrial and Engineering Chemistry, Institute of Chemical Technology, Indianoil Odisha Campus, Bhubaneswar, India

Neelam Dhankar Department of Pharmaceutical Sciences, Starex University, Gurugram, Haryana, India

Orlando David Henrique dos Santos Laboratory of Phytotechnology, School of Pharmacy, Federal University of Ouro Preto (UFOP), Ouro Preto, Minas Gerais, Brazil

Damián Eduardo Pérez-Martínez Health Sciences Doctoral Program, Health Sciences Institute, University of Veracruz, Xalapa, Veracruz, México

Zohreh Firouzi Department of Nanotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

Ashish Kumar Garg Akal College of Pharmacy and Technical Education, Mastuana Sahib Barnala Road, Mastuana Sahib, Punjab, India

Yolanda Gonzalez Department of Research in Microbiology, National Institute of Respiratory Diseases, Mexico City, Mexico

Bapi Gorain School of Pharmacy, Faculty of Health and Medical Sciences, Taylor's University, Subang Jaya, Selangor, Malaysia

Silvia Guzmán-Beltrán Department of Research in Microbiology, National Institute of Respiratory Diseases, Mexico City, Mexico

Mayank Handa Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research—Raebareli, Lucknow, India

Ali Ibrahim Bekraki Faculty of Pharmacy, Jinan University, Tripoli, Lebanon

Esmeralda Juárez Department of Research in Microbiology, National Institute of Respiratory Diseases, Mexico City, Mexico

Prashant Kesharwani Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard (Hamdard University), New Delhi, India

Farzad Khademi Department of Microbiology, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran

Mradul Mohan ICMR-National Institute of Malaria Research, New Delhi, India

Nagashekhara Molugulu School of Pharmacy, Monash University, Jalan Lagoon Selatan, Bandar Sunway, Selangor, Malaysia

Mohamad Mosa Mubarak Infectious Diseases PK/PD Lab, Life Science Block, Indian Institute of Integrative Medicine, Srinagar, Jammu and Kashmir, India

Ramakanta Naik Department of Engineering and Materials Physics, Institute of Chemical Technology, Indianoil Odisha Campus, Bhubaneswar, India

Bernadette Dian Novita Department of Pharmacology and Therapy, Faculty of Medicine, Widya Mandala Catholic University Surabaya, Surabaya, Indonesia

Rupal Ojha Department of Biochemistry, Central University of Rajasthan, Ajmer, Rajasthan, India

Rajan Kumar Pandey Department of Biochemistry, Central University of Rajasthan, Ajmer, Rajasthan, India

Sreenivas Patro Sisinthy School of Pharmacy, Faculty of Health and Medical Sciences, Taylor's University, Subang Jaya, Selangor, Malaysia

Vijay Kumar Prajapati Department of Biochemistry, Central University of Rajasthan, Ajmer, Rajasthan, India

Amal Rabti Sensors and Biosensors Group, Laboratory of Analytical Chemistry and Electrochemistry (LR99ES15), Department of Chemistry, University of Tunis El Manar, Tunis, Tunisia

Amal Raouafi Sensors and Biosensors Group, Laboratory of Analytical Chemistry and Electrochemistry (LR99ES15), Department of Chemistry, University of Tunis El Manar, Tunis, Tunisia

Noureddine Raouafi Sensors and Biosensors Group, Laboratory of Analytical Chemistry and Electrochemistry (LR99ES15), Department of Chemistry, University of Tunis El Manar, Tunis, Tunisia

Eupa Ray Institute of Nano Science and Technology (INST), Mohali, Punjab, India

Deviprasad Sahoo Department of Engineering and Materials Physics, Institute of Chemical Technology, Indianoil Odisha Campus, Bhubaneswar, India

Aakriti Sethi Department of Chemistry and Applied Biosciences, ETH Zurich, Zürich, Switzerland

Noorsuzana Mohd Shariff Advanced Medical and Dental Institute, Universiti Sains Malaysia, Kepala Batas, Penang, Malaysia

Ankur Sharma Institute of Nano Science and Technology (INST), Mohali, Punjab, India

Farideh shiehzadeh Department of Nanotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

Rahul Shukla Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research—Raebareli, Lucknow, India

Sima Singh Discipline of Pharmaceutical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa

Mohsen Tafaghodi Department of Nanotechnology, School of Pharmacy, Mashhad University of Medical Sciences; Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

Pushpendra K. Tripathi Rameshwaram Institute of Technology and Management, Lucknow, India

Kalpesh Vaghasiya Institute of Nano Science and Technology (INST), Mohali, Punjab, India

Rahul Kumar Verma Institute of Nano Science and Technology (INST), Mohali, Punjab, India

Roberto Zenteno-Cuevas Public Health Institute, University of Veracruz, Xalapa, Veracruz, México

Preface

Tuberculosis (TB) is a leading chronic bacterial infection. Despite potentially curative pharmacotherapies being available for over 50 years, the length of the treatment and the pill burden can hamper patient lifestyle. Prolonged treatment, high pill burden, low compliance, and stiff administration schedules are factors that are responsible for the emergence of multidrug-resistant strains. According to WHO reports, 53 million TB patients died from 2000 to 2016. Therefore, early diagnosis of the disease is of great importance for global health care programs. Various unique antibodies have been developed to overcome drug resistance, reduce the treatment regimen, and elevate the compliance to treatment. Therefore, we need an effective and robust system to subdue technological drawbacks and improve the effectiveness of therapeutic drugs which remains a major challenge for pharmaceutical technology.

Regarding TB treatment, nanoparticles can be a useful strategy for two distinct applications: (1) for their intrinsic antimycobacterial activity and (2) as vehicles for known antitubercular drugs to allow the reduction of dose- and drug-associated side-effects and administration via user-friendly administration routes such as pulmonary or oral ones.

This book will summarize the types of nano-drugs, their synthesis, formulation, characterization, and applications, with the most important administration routes. Thus, this book will discuss various nanotechnology-based approaches which may help overcome persisting limitations of conventional/traditional treatment. Also, recent advances and achievements regarding therapeutic efficacy provide possible future applications in this field. In this scenario, this book will directly address all translational aspects and clinical perspectives of TB nanomedicine from a comprehensive and multidisciplinary perception. This book is thus (1) an unrivalled, comprehensive summary of the field and (2) rationally conceived clinical stage of TB nanomedicines. The editor and contributors (authors) cover a wide range of expertise in the nanomedicine and TB and all of them are already proven their international acclaim.

We thank all the authors for their valuable and timely contributions. We believe that the book, with its comprehensive coverage of fundamental and applied aspects of the subject, will prove immensely useful to its readers and stimulate further interest.

Prashant Kesharwani

Nanotechnology approach in conquering anti-TB resistance

Bernadette Dian Novita

Department of Pharmacology and Therapy, Faculty of Medicine, Widya Mandala
Catholic University Surabaya, Surabaya, Indonesia

Abbreviations

AFB Acid Fast Basil
MDR-TB multidrug resistant tuberculosis
M.tb *Mycobacterium tuberculosis*
TB tuberculosis
XDR-TB extra-drug resistant tuberculosis
RIF rifampicin
INH isoniazid
PYR pyrazinamide
ETB ethambutol

1 *Mycobacterium*: pathogenesis and its problem in the resistant

Tuberculosis (TB) is an air-borne chronic infection caused by *Mycobacterium tuberculosis* (M.tb). It has a high affinity to the parenchymal tissue of lungs due to the high oxygen level. *Mycobacterium tuberculosis* (M.tb) is a Gram-positive acid-resistant stem and called Acid Fast Basils (AFB). The golden standard in identified TB infection is the count of AFB smears from sputum, for TB in the lung or other specimens, for extrapulmonary TB [1].

Pathogen M.tb is easily to die with direct sunlight. However, it survives in dark and damp places, even it is outside the host. *Mycobacterium tuberculosis* transmits through aerosol droplets from coughing, sneezing, or saliva splashes of people infected TB lungs. The droplet diameter is very small (0.5-5 μm) and around 40,000 bacteria are produced each sneezing, therefore M.tb eases to transmitted [1].

After the inhalation of *M. tuberculosis*, innate immune responses involving alveolar macrophages and granulocytes begin to combat the infection; in some persons, the bacilli are cleared, whereas in others, infection is established [2]. The replication of bacilli in macrophages and regional lymph nodes leads to both lymphatic and hematogenous dissemination, with seeding of multiple organs, which may eventually give rise to extrapulmonary disease. The containment of bacilli within macrophages and extracellularly within granulomas limits further replication and controls tissue destruction, resulting in a dynamic balance between pathogen and host. The classic interpretation of this as a binary

process with either truly latent *M. tuberculosis* infection or active tuberculosis disease has recently been challenged as an oversimplification. Instead, a spectrum of immunologic responses that are both protective and pathogenic and correlate with a range of bacterial activation has been suggested. This continuum encompasses a variety of host-microbe interactions, which are characterized by clinical latency when host responses predominate and by disease when bacterial replication exceeds the threshold required to cause symptoms [2-4]. Recent evidence suggests that host inflammatory responses, particularly with interleukin-1 β , may actually enhance mycobacterial replication, which illustrates that the double-edged sword of immune responses seen in tuberculosis disease may also be present in latent infection (as shown in Fig. 15.1).

Mycobacterium tuberculosis forms into an active, clinically silent, and latent infection. It said that one-third of the world's population infected by M.tb, most of them are asymptomatic and become latent tuberculosis infection especially in people with immunocompromised conditions, for example, HIV/AIDS, DM, malnutrition, on

chemotherapy or steroids therapy, and antitumor therapy necrosis factor. Only about 5%-10% suffer from active tuberculosis infection [1].

Tuberculosis (TB), the infection caused by *Mycobacterium tuberculosis* (M.tb), remains a problem to overcome in Indonesia. In East Java Province Indonesia 2018, the incidence of new TB cases reached 767 from 100,000 population [6]. This phenomenon was similar to TB incidence in the world. According to the World Health Organization (WHO) data in 2013, it states that the incidence of new TB cases in the world has increased 50%, and therefore WHO has declared for TB as a "global health emergency" [7]. The pathology mechanism of TB could be seen in Fig. 15.2.

Mycobacteria, especially *Mycobacterium tuberculosis* (M.tb), are intrinsically resistant to most antibiotics [9]. They have the ability in growing slower than other bacteria. There is no single antibiotic that is relatively effective against M.tb, therefore for tuberculosis (TB) multidrugs therapy (MDT) is required to avoid bacterial resistant [9,10]. Mycobacterial cells are lipid-rich and also able to be dormant that causes impermeable and poorly penetrate for many agents, including macrophages.




FIGURE 15.1 The main subcellular events of *M. tuberculosis* infection in macrophage [5].




FIGURE 15.2 Pathology of tuberculosis [8].

Finally, *M. tuberculosis* has the ability to manipulate both innate and adaptive immune response and called TB's escape mechanism. In this mechanism, *M.tb* has a high ability to avoid intracellular killing process and macrophage phagocytosis process [11,12]. Mycobacteria are notorious for their ability to develop resistance [9,10]. Moreover, phagosome maturation, which is activated during *M.tb* recognition process, is the decrease of intra-vacuole pH, from ~ 7 to 5. This acidification represents a fundamental blocking step in the process of bacterial elimination [5].

The worldwide emergence and spread of drug-resistant *M. tuberculosis* strains is a serious concern considering the high death rate associated with such infections. To tackle this issue, new therapeutic molecules and vaccination/prevention strategies have to be developed. However,

such developments may require a better understanding of how *M. tuberculosis* blocks the innate defenses of the host to establish its intra-cellular replicative niche [5].

2 Antituberculosis and the mechanism of antituberculosis resistant

The aims of antituberculosis (anti-TB) are (1) to cure the patient; (2) to prevent death; (3) to prevent recurrence; (4) to break the chain of transmission; and (5) to prevent *M.tb* resistant. Mycobacterium has ability to grow very slowly and develop resistance rapidly. Therefore, to treat TB, several combinations or TB-MDT are needed.

Tuberculosis MDT is classified into two lines: the first line of TB MDT is rifampicin (RIF),

isoniazid (INH), pyrazinamide (PYR), ethambutol (ETB), and streptomycin. This group of drugs exhibits high effectiveness with acceptable toxicity [9,10,13]. The second line of TB-MDT is the antibiotics fluoro-quinolones (such as ciprofloxacin, ofloxacin, levofloxacin, moxifloxacin), macrolides (such as erythromycin, clarithromycin), and aminoglycosides (such as amikacin, kanamycin, and capreomycin) [9,10,13].

The aims of TB-MDT are (1) to increase bactericidal activity, starting from the beginning of therapy phase; (2) to prevent drug resistant; and

(3) to enhance the process of eliminating *M. tuberculosis* in the sites of TB infection [9,10,13].

Isoniazid is the primary drug for chemotherapy of TB infection with the highest bactericidal activity at the beginning of TB treatment. All patients infected with isoniazid-sensitive strains of the tubercle bacillus should receive the drug if they can tolerate it. The use of combination therapy (isoniazid + pyrazinamide + rifampin) provides the basis for “short-course” therapy and improved remission rates [9,10]. The mechanism of action of anti-TB could be seen in Fig. 15.3.




FIGURE 15.3 Mechanism of pharmacotherapy in tuberculosis [8].

The isoniazid's efficacy gets higher when it combined with ethambutol, rifampicin, pyrazinamide, and streptomycin. Rifampicin has the highest elimination ability of *M. tuberculosis*. Isoniazid enters bacilli by passive diffusion. The drug is not directly toxic to the bacillus but must be activated to its toxic form within the bacillus by KatG, a multifunctional catalase-peroxidase. KatG catalyzes the production from isoniazid of an isonicotinoyl radical that subsequently interacts with mycobacterial NAD and NADP to produce a dozen adducts. One of these, a nicotinoyl-NAD isomer, inhibits the activities of enoyl acyl carrier protein reductase (InhA) and -ketoacyl acyl carrier protein synthase (KasA). Inhibition of these enzymes inhibits synthesis of mycolic acid, an essential component of the mycobacterial cell wall, leading to bacterial cell death. The products of KatG activation of INH include superoxide, H₂O₂, alkyl hydroperoxides, and the NO radical, which may also contribute to the mycobactericidal effects of INH. *M. tuberculosis* could be especially sensitive to damage from these radicals because the bacilli have a defect in the central regulator of the oxidative stress response, *oxyR*. Backup defense against radicals is provided by alkyl hydroperoxide reductase (encoded by *ahpC*), which detoxifies organic peroxides. Increased expression of *ahpC* reduces isoniazid effectiveness [10]. The antibacterial effect of isoniazid against clinical M.tb strains varies between 0.025 and 0.05 mg/L. Activity against *Mycobacterium bovis* and *M. kansasii* is moderate. Isoniazid has poor activity against MAC. It has no activity against any other microbial genus [10]. The prevalence of drug-resistant mutants is ~1 in 10⁶ bacilli. TB cavities may contain as many as 10⁷ to 10⁹ microorganisms; preexistence resistance can be expected in pulmonary TB cavities of untreated patients. These spontaneous mutants can be selected by monotherapy; indeed, strains resistant to isoniazid will be selected and amplified by isoniazid monotherapy. Thus two or more agents are usually used. The mutations result-

ing in drug resistance are independent events, the probability of resistance to two antimycobacterial agents is small, ~1 in 10¹² (1 × 10⁶ × 10⁶), a low probability considering the number of bacilli involved. Resistance to INH is associated with mutation or deletion of *katG*, overexpression of the genes for *inhA* (confers low-level resistance to INH and some cross-resistance to ethionamide), and *ahpC* and mutations in the *kasA* and *katG* genes. KatG mutants exhibit a high level of resistance to isoniazid (as shown in Fig. 15.4).

Rifampicin inhibits the growth of most Gram-positive bacteria as well as many Gram-negative microorganisms such as *Escherichia coli*, *Pseudomonas*, indole-positive and indole-negative *Proteus*, and *Klebsiella*. Rifampicin is very active against *Staphylococcus aureus* and coagulase-negative staphylococci. The drug also is highly active against *Neisseria meningitidis* and *Haemophilus influenzae*. Rifampicin inhibits the growth of many *M. tuberculosis* clinical isolates in vitro at concentrations of 0.06-0.25 mg/L [10]. The prevalence of rifampicin-resistant isolates is 1 in every 10⁷ to 10⁸ bacilli. Microbial resistance to rifampin is due to an alteration of the target of this drug, *rpoB*, with resistance in 86% of cases due to mutations at codons 526 and 531 of the *rpoB* gene [10]. Pyrazinamide is the synthetic pyrazine analog of nicotinamide. Pyrazinamide is also known as pyrazinoic acid amide, pyrazine carboxylamide, and pyrazinecarboxamide. Pyrazinamide is "activated" by acidic conditions. Initially it was assumed that the acidic conditions under which pyrazinamide works were inside macrophage phagosomes. However, pyrazinamide may not be very effective within macrophages; rather, the acidic conditions for activation may be at the edges of necrotic TB cavities where inflammatory cells produce lactic acid. *M. tuberculosis* nicotinamidase or pyrazinaminidase deaminates pyrazinamide to pyrazinoic acid (PO₃⁻), which is then transported to the extracellular milieu by an efflux pump. In an acidic extracellular milieu, a




FIGURE 15.4 Mechanism of action of isoniazid [10].

fraction of POA⁻ is protonated to POAH, a more lipid-soluble form that enters the bacillus. The actual mechanism of pyrazinamide microbial kill is still unclear; three mechanisms have been proposed [10]:

1. inhibition of fatty acid synthase type I leading to interference with mycolic acid synthesis,
2. reduction of intracellular pH, and
3. disruption of membrane transport by HPOA.

Antibacterial activity of pyrazinamide *in vitro* only at acidic pH. At pH of 5.8-5.95, 80%-90% of clinical isolates have a MIC of 100 mg/L. Pyrazinamide-resistant occurs when *M.tb* has pyrazinamidase to reduce affinity for pyrazinamide. This reduced affinity decreases the conversion of pyrazinamide to POA. Single point mutations in the *pncA* gene are encountered in up to 70% of resistant clinical isolates. The mechanisms

contributing to resistance in 30% of resistant clinical isolates is unclear [10].

Ethambutol inhibits arabinosyl transferase III, thereby disrupting the transfer of arabinose into arabinogalactan biosynthesis, which in turn disrupts the assembly of mycobacterial cell wall. The arabinosyl transferases are encoded by *embAB* genes. Ethambutol has activity against a wide range of mycobacteria but no activity against any other genus. Ethambutol MICs are 0.5-2 mg/L in clinical isolates of *M.tb* [10]. *In vitro*, mycobacterial resistance to the drug develops via mutations in the *embB* gene. In 30%-70% of clinical isolates that are resistant to ethambutol, mutations are encountered at codon 306 of the *embB* gene. However, mutations in this codon are also encountered in ethambutol-susceptible mycobacteria, as though this mutation is necessary, but not sufficient, to confer ethambutol resistance [10].

A combination of isoniazid-rifampicin for 9 months administration will cure 95%-98% of cases of tuberculosis infection caused by susceptible strains [9]. An initial intensive phase of treatment is recommended for the first 2 months due to the prevalence of resistant strains. The addition of pyrazinamide during this intensive phase allows the total duration of therapy to be reduced to 6 months without the loss of efficacy. In practice, therapy is usually initiated with a four-drug regimen of isoniazid, rifampicin, pyrazinamide, and ethambutol until susceptibility of the clinical isolate has been determined. In susceptible isolates, the continuation phase consists of an additional 4 months with isoniazid and rifampicin [9]. However, isoniazid and rifampicin are the TB-MDT that experiences resistant frequently.

The resistance of TB-MDT arises through several mechanisms [10] (as shown in Fig. 15.5), including:

1. The inability of TB-MDT to penetrate into *M. tuberculosis*' wall cells by reason of its rich lipopolysaccharide and mannose.
2. The anaerobic conditions in the site of infection enable *M. tuberculosis* to become dormant. The TB-MDT, especially isoniazid, is ineffective in dormant conditions.
3. Alteration of enzymes that produced by M.tb. These enzymes prevent the conversion of prodrugs into active drugs. Isoniazid inhibits the synthesis of mycolic acids, which are essential components of mycobacterial cell walls. Isoniazid is a prodrug that is activated by KatG, the mycobacterial catalase-peroxidase. The activated form of isoniazid forms a covalent complex with an acyl carrier protein (AcpM) and KasA, a beta-ketoacyl carrier protein synthetase, which blocks mycolic acid synthesis. Resistance to isoniazid is associated with mutations resulting in overexpression of




FIGURE 15.5 Mechanism of TB-MDT resistance [10].

inhA, which encodes an NADH-dependent acyl carrier protein reductase; mutation, or deletion of the *katG* gene; promoter mutations resulting in overexpression of *ahpC*, a gene involved in the protection of the cell from oxidative stress; and mutations in *kasA*. Overproducers of *inhA* express low-level isoniazid resistance and cross-resistance to ethionamide. *KatG* mutants express high-level isoniazid resistance and also pyrazinamide resistance.

4. Alteration of target protein structures. This prevents drug recognition (rifampicin, ethambutol, fluoroquinolones, macrolides).
5. Drug exported from the cell before reaching the sites of infection (isoniazid, ethambutol, streptomycin).
6. Mutation in DNA repair gene that leads the multidrug resistance (MDR)-TB.

Those all aforementioned mechanisms reduce the efficacy of TB-MDT.

3 Nanoparticle and its use to conquer tuberculosis infection

Nanotechnology is an innovative use of the latest technological developments or nanoparticle sized. Nowadays, it has a major impact for health and therapeutic development. The nanoparticle now is known as a drug delivery system, thus it enhances the drug efficacies [14].

In the process of diagnosis, nanotechnology may play a role in the diagnostic kit. For example in India, The aid of TB diagnosis created diagnostic kits in an optical biosensor for rapid detection of *M.tb* bacilli [14,15].

In the TB treatment, nanotechnology has a huge improvement in pharmacology, especially in the delivery system. The TB-MDT is able to reach the site of infection and impact to the function of macrophage and other phagocyte cells. Nanoparticle gives advantages such as combining MDT into one form, reducing the frequency

of drugs, increasing the therapeutic index of anti-TB, increasing the solubility of hydrophobic agents capability, and reducing the administration of higher doses [16]. As drug delivery, nanoparticles also give other advantages such as, improve drug stability, improve the ability of carrier molecules, and the feasibility of incorporation of both hydrophilic and hydrophobic substances. Reviewing these carriers can also be designed to enable controlled (sustained) drug release from the matrix [16].

Nanoparticles as a therapeutic include; nanoemulsions, nanosuspensions, niosomes, polymeric micelles, and other self-assembled structures, are roommates antituberculosis drug nanocarriers, and polymeric and nonpolymeric nanoparticles. Nanoparticles can penetrate the intestinal permeability barrier directly through the transcellular or paracellular pathways into the circulation. This work makes drugs more and more effective. Nanosuspensions are a potential and promising new anti-TB drug formulations for intravenous way. Nanoparticles are able to achieve the higher stability and ability of the drugs, the feasibility of incorporating both hydrophobic and hydrophilic substances, and the feasibility of any administration routes such as parenteral, oral, and inhalation [15].

Nanotechnology increases the bioavailability of drugs as a result of a special absorption such as the absorption mechanism of endocytosis. The nanoparticles are also able to remain in the blood for a longer period of time and in controlled release manner into the target tissue. The self-control system of release of the drug helps reduce fluctuations in plasma and minimize side effects of the drug. In the case of TB adverse effects of tuberculosis drugs became one of the causes in poor compliance [17].

Nowadays, nanoparticle also develops in order to diminish the number of MDR-TB cases. There is a strong urge to develop novel ways of delivering the therapeutic compounds to the specific target of making the drug more effective [14].

Currently, the basic mechanism of controlled drug release was established and most drug delivery formulations were oral and transdermal administration. The effectiveness and stability were low in these drug systems. The effectiveness and stability of the drug will affect drug action and its effect on the patient's body. The drug is incorporated into the nanoparticle that easily diffused through biological membranes and cells take up. These particles for the efficiency in drug delivery to the site of action. Nanotechnology improves the performance of the effectiveness of the drug, in patients taking the drug longer, and cost-effectiveness. Nanotechnology can produce biodegradable, biocompatible polymers, stimulate, and targeted by following the intended target organs, such as liposomes deliver responsive, nanofabricated materials (fullerenes, carbon nanotubes, silicon, silica), metals (gold, silver, iron, platinum, quantum dots), and polymers (micelles, dendrimers). Nanoparticles shape assortment such as spherical, rods, wires, discs, hemispherical, and ellipsoidal [17].

The size of the nanoparticles that less than submicron ($<1 \mu\text{m}$) colloidal particles are used as drug delivery vehicles. For therapeutic purposes, drugs can be covalently embedded to the particle surface or can be incorporated in the matrix of the particle. Nanoparticles comprise biocompatible and biodegradable materials such as polymers, which can be natural (e.g., gelatin and albumin), synthetic (e.g., polylactides and polyalkylcyanoacrylates), or solid lipids. Nanoparticles have a higher efficiency of the cells compared to the molecules in the case of a delivery system. Nanoparticle delivery system has capabilities that are more specific and faster. These carriers that are adapted to enable controlled, slow, and persistent drug release from the matrix [18]. The nanoparticle expresses in the gene and able to trace into the DNA complexes track (in vivo), this advantage is important in simultaneously dosage administration and determination. In this determination system, the nanoparticle has a high sensitivity

to measure the level of gene expression (in vivo imaging) and is also able to target the specific/diseased cell types [14].

Nanoscience is a new perspective in making early detection, prevention, diagnosis, and treatment in TB became easier and more effective. This is because nanoscience has the potential to empower local responses to specific targets and other benefits to save costs. Nanoparticle-based gene therapy and drug delivery hold a great promise for the sound management of diseases in terms of improved drug bioavailability and reduced dosing frequency, though it is extremely important to investigate the toxic effects nanoparticles according to chemistry, size, and other physical properties [14].

Future holds up in designing of drug-delivery systems or formulations roommates can resolve all the limitations of tuberculosis drug therapy and making them affordable to all patients. Several antitubercular drugs encapsulated in natural or synthetic carrier-based controlled release formulations have been explored and nanoparticles appeared to be the best in terms of therapeutic efficacy [14].

Developing research related to vector-based delivery systems could combine roommates colloidal carriers such as large payloads of drug with the active targeting to improve the effectiveness and efficiency of drug action based on the nanoparticle-based formulations. Understanding the fate of nanocarriers and their polymeric constituents along with the elimination of any residual organic solvents is a must for dealing with any toxicological issues associated with these nanoformulations [14].

Nanoparticle delivery system is a promising key for the media but it is also against drug-susceptible tuberculosis and drug resistance. Nanoparticles are also useful for reducing the burden on the patient's dose but have the same benefits, but simultaneously. Nanotechnology still has a lot of homework for future challenges especially for TB. Lots of health gaps need to be filled along with global sustained efforts to

overcome TB infection, in order to reach the site of infection in the secondary lymphoid organs [14].

Increasing incidence of multidrug-resistant strains make research related to ways of delivering the therapeutic compounds to the specific target of growing. Many delivery systems, such as nanoemulsions, nanosuspensions, polymeric and nonpolymeric particles, liposomes, niosomes, and dendrimers, have been developed in the past, overcoming many of the shortcomings of the delivery of conventional drugs [14].

4 Function nanoparticle for overcoming resistance tuberculosis treatment

TB drug resistance is the inability of the existing TB drugs to phagocyte mycobacterium that exists in the patient's body, due to the growing strength of *Mycobacterium tuberculosis* that is inside the patient's body TB [19].

Mycobacterium tuberculosis is one of the most infection disease which successful human pathogens, due to its ability to carry a primary infection to a state of dormancy (latents), persisting in the body even in immune-competent people. In this regard, it is important to mention that there are two billion people infected worldwide by M.tb, and only nine million people develop into TB clinical diseases, for example: from 100 people whom were exposed with M.tb, only 2 persons grow into clinical TB infection, this phenomenon is due to immune response. TB is usually a lung disease, due to the fact that these organs are the gateway and provide optimal conditions for the infected of this disease. The primary infection begins with the inhalation of the particles of *Mycobacterium tuberculosis*. Approximately 10% of this invasion due to respiratory tract that are in alveoli and bronchioles, where the bacteria is recognized and phagocytosed by alveolar macrophages (AMs) or dendritic cells (DCs). Macrophages exposed to *Mycobacterium tuberculosis* secrete pro-inflammatory cytokines (IL-1, TNF- α , and IL-6) that

will contribute to the subsequent formation of focal granulomatous lesions, a process that takes 2-3 weeks, and which generally leads to the containment of the pathogen [8].

Pharmacotherapy of tuberculosis therapeutic regimen is recommended by the WHO for susceptible pulmonary TB rifampicin, isoniazid, pyrazinamide, ethambutol, and streptomycin. The therapy in tuberculosis consists of a short-term treatment of 6 months (divided into two stages), intensive phase and continue phase [8,10,20]. Drug chemical structures could be seen in Fig. 15.6.

Tuberculosis drug resistance or multidrug resistant tuberculosis (MDR TB) is a condition in which a patient is resistant to first-line TB treatment. The first-line drug is a list of the first drug given to patients with TB occurrence. This is because of the resistance of patients who dropped out treatment or in patients who are infected with *Mycobacterium tuberculosis* for the umpteenth time. The inability of antituberculosis (anti-TB) has become one of the causes in which a patient MDR-TB or now known by extra-drug resistant tuberculosis (XDR-TB) must increase the dosage of antituberculosis drugs and make the treatment of TB becomes longer. The efficacy of anti-infective drugs is not only dependent on the pathogens related to MIC, but also on the exposure of the drug in the patient [21].

Combination of nanomaterials with the understanding of differentiation of biological processes, nanotechnology could ameliorate and trigger the usage of brand new drug/antigen in delivery systems. Based on evidence nanomaterials have a result better than liposomes, there about stabilization and drug loading capacity. The differentiation of nanoformulations, like lipid-based and (branched) polymeric ones, is being explored to deliver different types of drugs. In recent years, many efforts have been directed to the encapsulation of anti-TB drugs within nanoparticles [8].

Low compliance, the main cause that makes the incidence of drug resistance to anti-TB




FIGURE 15.6 Pharmacotherapy of tuberculosis [10].

against *Mycobacterium tuberculosis*, is increasing. Now it has become clear that pharmacokinetic variability is much more likely to be the driving force of drug resistance. The development of pharmacokinetic required in the case of anti-tuberculosis drug resistance (anti-TB). If the existing infection with TB addressed adequately, then the bacteria will not occur and can be treated. However, in the case of anti-TB drugs, a therapeutic range or the target has not been established.[21].

Nanoparticles are believed to increase the significance of the treatment of TB from diagnosis, treatment, and prevention. Nanotechnology is

one of the functions that improve nanomedicine. Due to reviews, their size, shape, and morphology (less than 100 nm in one aspect) nanoparticles exhibit different properties of the same material when they are in bulk size. New diagnostics and therapeutics for application in organ systems have been developed due to the unique properties of nanopharmaceuticals [22].

Nanomedicine approaches are being used as effective carriers of drugs to different parts of the body that were previously difficult to access. Nanomedicine approach in anti TB enhances the efficacy of the drugs. It may possible to the target nanoparticles to specific organs by modifying

the elemental composition, size, shape, charge, and surface modification or functionalization [22].

That brings us to the second reason why we need new anti-TB drugs. Drug resistance has emerged as a phantom from the dark, threatening today every corner of the world. Often RIF-resistance correlates to the MDR category (resistant to INH and RIF). XDR is an MDR *M. tuberculosis* strains resistant to any fluoroquinolone also and at least one injectable agent. The prognosis is less favorable for harboring XDR-bacilli patients compared to patients with MDR, with a five times higher risk of death, therefore the XDR patients need to be hospitalized or requires longer treatment times. However, it has been shown that within an aggressive treatment, XDR-TB patients have been successfully cured by 60%. The treatment of M/XDR-TB usually takes more than 2 years, and requires the use of more toxic, less effective, and more expensive drugs [15].

Pulmonary tuberculosis is the most ubiquitous form of the disease, and the respiratory path represents the means of delivering a unique ATD's directly to the lungs. The reduction of toxicity and accomplishing higher systemic drug concentration at the chief site of infection are the promising advantages of the direct delivery of the drug to the lungs. Inhalable nanoparticles possess an enhanced ability of mucosal adherence, particle delivery, and net drug delivery to the lungs [23].

Anti-TB drug carriers are classified: synthetic or natural origin. They allow the flexibility of selecting the route of drug delivery, Depending on the drug formulation. Not only the smaller size but also the ability of higher drug encapsulation and enhancement of the orally administered-drug bioavailability is the key difference between the nanoparticles and microparticles. poly-DL-lactide-co-glycolide (PLG)-A nanoparticles are commonly used in preparation for emulsification or evaporation [15].

Nanomedicine approach significantly prolonged provided a mean residence time, and elimination half-life of the drugs in comparison to the conventional orally administered formulations and resulted in an enhanced relative bioavailability for the nanoparticle-preparations (rifampicin, pyrazinamide, and isoniazid). The nebulization of the nano-encapsulated drug led to an absence of *Mycobacterium tuberculosis* in the lungs [17].

Drug resistance tuberculosis is an important health issue in progress made in TB care and control programs worldwide. Drug resistance arises due to pathogen inappropriate use of medicines in the treatment of drug-susceptible tuberculosis patients. This improper use may be due to the administration of improper treatment regimens and the failure of noncompliance of the patients to complete the course of therapy [17].

The treatment of tuberculosis has become a challenge for the physicians because of the emerging threat of drug-resistant strains of the pathogen. The *M. tuberculosis* responsible for the disease can overcome the cellular defense mechanisms, infecting the cells and turning them into reservoirs. The drawbacks of conventional tuberculosis drug formulation are the inability to kill the intracellular pathogens because of reviewing their limited bioavailability and limited penetration power in the targeted pathogens to produce a therapeutic effect [17].

Nanomedicine has the potential to challenge such limitations and improve the therapeutic efficacy of such drugs. Nanovesicles formulation of gentamicin, vancomycin amikacin, kanamycin, streptomycin, present enhanced in vitro and in vivo efficacy. Reviewing these formulations successfully reduced the viable bacteria counts of *M. tuberculosis*. However, in some cases, the pulmonary availability of the drugs was small or absent roommates can overcome by the development of localized particles targeted for delivery by inhalation or by targeting the pulmonary area [17].

5 Nanoparticle for diagnose tuberculosis

Diagnose tuberculosis with detection of mycobacterium DNA in clinical samples using nanoparticles has been developed, and it is a great futuristic vision. Nanocrystalline silicon photodetector with suitable software can detect tuberculosis for diagnose tuberculosis and it could be to lessen the human error in diagnose tuberculosis. Recently, a convenient and low-cost biosensing platform was presented to detect *Mycobacterium tuberculosis* [24].

Exploited of scanobased, fluoremetric, colorimetric, surface-enhanced Raman scattering and electrochemical methodologies as a ultrasensitive techniques can developed to detect gold nanoparticles in clinical sputum samples, which that engineered with thiol-modified oligonucleotides to make the detection efficient, simplified, and relatively cheaper. *Mycobacterium tuberculosis* can be easily differentiated from other members of Mycobacterium species with the help of these nanoparticles. Fluorescent semiconductor quantum dots and magnetic beads are also used to detect DNA of Mycobacterium species

without prior PCR. Even the probe consisting of superparamagnetic ironoxide nanoparticles has been designed and this probe is specific for diagnosing the extrapulmonary TB [24].

Nanoparticles are versatile and diverse with respect to their properties and structural, which enables them to be used for clinical diagnosis and effective drug delivery purpose in a unique and more reliable manner. Owing to their wide range of distribution manner and functional modes, nanoparticles can be used for multiple applications. The main reason behind this is the excellent geometric control of structures by arresting their formation during different stages of their synthesis. Better and more effective disease treatment protocols can be achieved with the use of systems like programmable nanorobots that can be employed for site-specific drug delivery [24].

Dendrimers has a layer, outer core on dendrimers there has hydrophilic characteristic and on an inside core on dendrimers has hydrophobic characteristic, so possible to deliver material component (as shown in Figs. 15.6 and 15.7). This arrangement forms the basic formulation




FIGURE 15.7 Different nanotechnology-based approaches [8].




FIGURE 15.8 Dendrimers based nanotechnological treatment [8].

for dendrimers in drug delivery systems. *Mycobacterium* is a Gram-negative bacterium. Its cell-wall composition (a rich layer of mycolic acid) renders it difficult for potential anti-TB medicinal preparations to enter into the infected cells. With the use of dendrimers, the conformation of the carried medicinal formulation is biochemically altered in a way that favors its entry into the specific target cells [24].

Nanoparticles have also been explored for the coencapsulation of tuberculosis drugs. Respiratory delivery developed because nanocarriers loaded with RIF, INH, and PYR. Data demonstrated that the inhalable nanotechnological platform allowed improving the pharmacotherapy regimen in *Mycobacterium tuberculosis* infected. Nanoparticles were investigated to encapsulate these tuberculosis drugs. Polymeric micelles (PMs) have become well-investigated nanovehicles. They are composed by amphiphilic biocompatible polymers that can self-assemble into nanostructures when the polymers concentration is above their critical micellar concentration. The pharmacotherapy of tuberculosis: this strategy has not been explored as LPs and NPs. The selection of the biomaterials and the pharmaceutical additives allowed developing different dosage forms (Figs. 15.8 and 15.9) [8].

Nanosuspension can make more efficient absorption and better biodistribution of drug molecules. During the formulation of a nanosuspension, the crystalline particles of the drug are converted into amorphous form. The conversion to amorphous forms can be achieved using X-ray diffraction. Various parameters such as particle size, charge distribution, and drug dissolution celerity also can be more effectively and easily monitored as well as suitably modified to suit a particular kind of drug delivery mechanism. Nanoemulsions represent a stable thermodynamic mixture. The use of rifampicin-based nanoemulsions for TB pharmacotherapy: they have elaborated the critical design features such as viscosity, solubility, and chemical interaction ability for nanoemulsion design to become optimized drug delivery vehicles. It has been successfully used for the killing of *Mycobacterium tuberculosis* germs at low dosage, and there is hardly any risk of toxicity or side effects (Fig. 15.10) [24].

There is a significant improvement from anti-TB drugs with nanoparticle than free anti-TB drugs. Relativity, bioavailability and mean residence time of encapsulated drugs more significant. Five aerosolized doses of PLG nanoparticles coencapsulating rifampicin, isoniazid, and pyrazinamide revealed undetectable cfu in the lungs. Comparison with microparticles: first, the decrease of lung cfu was better, and second, coadministration of three anti-TB drug encapsulations was possible in nanoparticles delivery system. As detection of *Mycobacterium tuberculosis* nanotechnology more expendable and efficient, especially high sensitivity so diagnose of tuberculosis more effective and efficient because nanoparticles can be tagged with suitable ligands and can be functionalized with various lectins to make more effective PLG nanoparticle uptake [15].




FIGURE 15.9 Nanomedicine in tuberculosis [8].




FIGURE 15.10 Mechanism of both natural and synthetic drug carriers by nanoparticle [14].

References

- [1] A.K. Abbas, A.H. Lichtman, S. Pillai, *Cellular and Molecular Immunology*, sixth ed. Saunders, Philadelphia, 2012.
- [2] E. Campion, Latent *Mycobacterium tuberculosis* infection Haileyesus, *N. Engl. J. Med.* 370 (22) (2015) 2127–2135.
- [3] B.I. Restrepo, L.S. Schlesinger, Host-pathogen interactions in tuberculosis patients with type 2 diabetes mellitus, *Tuberculosis* 93 (2013) S10–S14, doi: 10.1016/S1472-9792(13)70004-0.
- [4] S.S. Stew, P.J. Martinez, L.S. Schlesinger, B.I. Restrepo, Differential expression of monocyte surface markers among TB patients with diabetes co-morbidity, *Tuberculosis*. 93 (2013) S78–S82, doi: 10.1016/S1472-9792(13)70015-5.
- [5] Pusat Data dan Informasi Kementerian Kesehatan RI, *Tuberkulosis*. Kementerian Kesehatan RI, Jakarta, 2018.
- [6] World Health Organization Guidelines for surveillance of Drug Resistance in Tuberculosis, fifth ed., WHO Publications, (2015).
- [7] E. Grotz, N. Tateosian, N. Amiano, M. Cagel, E. Bernabeu, D.A. Chiappetta, et al. Nanotechnology in tuberculosis: state of the art and the challenges ahead, *Pharm. Res.* 35 (2018) 213.
- [8] B.G. Katzung, *Basic & Clinical Pharmacology*, fourteenth ed., McGraw-Hill Education, San Francisco, (2018).
- [9] B. Laurence, B. Chapner, B. Knollmann, *The Pharmacological Basis of Therapeutics*-Goodman & Gillman-Ed, twelfth ed., McGraw-Hill Companies, California, (2011).
- [10] A. Manuscript, C. Death, Cell death and autophagy in TB Andrew, *Semin. Immunol.* 26 (6) (2015) 497–511.
- [11] B.D. Novita, Metformin: a review of its potential as enhancer for anti tuberculosis efficacy in diabetes mellitus-tuberculosis coinfection patients, *Indian J. Tuberc.* 66 (2) (2019) 294–298, doi: 10.1016/j.ijtb.2019.02.013.
- [12] D. Golan, A. Tahjian, E. Armstrong, A. Armstrong, *Principles of pharmacology: the pathophysiologic basis of drug therapy*, third ed., Lippincott Williams & Wilkins, Philadelphia, (2012).
- [13] A.K. Sharma, R. Kumar, B. Nishal, Nanocarriers as promising drug vehicles for the management of tuberculosis nanocarriers as promising drug vehicles for the management of tuberculosis, *Bionanoscience* 3 (June) (2013) 102–111.
- [14] A. Cheepsattayakorn, C. Mai, Roles of nanotechnology in diagnosis and treatment of tuberculosis, *J. Nanotechnol. Diagn. Treat.* 1 (May) (2013) 19–25.
- [15] J.P. Mathuria, Nanoparticles in tuberculosis diagnosis, treatment and prevention: a hope for future, *Digest J. Nanomater. Biostruct.* 4 (2) (2009) 309–312.
- [16] J. Wanigasekara, C. Witharana, Applications of nanotechnology in drug delivery and design-an insight, *Curr. Trends Biotechnol. Pharm.* 1 (January) (2017) 78–91.
- [17] M. Nasiruddin, K. Neyaz, S. Das, Nanotechnology-based approach in tuberculosis treatment, *Tuberc. Res. Treat.* 2017 (2017) 1–12.
- [18] WHO, *Guidelines for Surveillance of Drug Resistance in TBC*, fifth ed., Switzerland, (2015) p. 76.
- [19] D. Resistance, T. Azimi, M. Mosadegh, M.J. Nasiri, S. Sabour, S. Karimaei, et al. Phage therapy as a renewed therapeutic approach to mycobacterial infections: a comprehensive review, *Infect. Drug Resist.* 12 (2019) 2943–2959.
- [20] P.C. Tan, G. Rajasingam, S. Devi, S.Z. Omar, Dengue infection in pregnancy: prevalence, vertical transmission, and pregnancy outcome, *Obstet. Gynecol.* 111 (5) (2008) 1111–1117.
- [21] J.D. Guzman, X. Montes-rincón, Research and development of new drugs against tuberculosis, in: *Tuberculosis-Current Issues in Diagnosis and Management*, Intech (2014) 331–358.
- [22] S. Banyal, P. Malik, H.S. Tuli, T.K. Mukherjee, Advances in nanotechnology for diagnosis and treatment of tuberculosis, *Wolters Kluwer Heal.* 19 (3) (2013) 289–297.

Index

Note: Page numbers followed by “f” indicate figures.

A

Adaptive immunity, 21
Adjuvanted subunit TB vaccine, 78
Advanced TB vaccine delivery systems
 cationic nanoparticle-based TB vaccine delivery, 83
 chitosan-based nanoparticle TB vaccine delivery, 83
 dendrimer-based TB vaccine delivery system, 85
 formulation and their delivery, 87
 immune stimulating complexes (ISCOMs) as a TB vaccine delivery system, 86
 liposome-based TB vaccine delivery, 85
 nanoparticles-based TB vaccine delivery systems, 82
 polymeric/polyester-based nanoparticle TB vaccine delivery system, 84
 virosomes-based TB vaccine delivery system, 87
 virus-like particles (VLPs)-based TB vaccine delivery system, 86
Aerosol-based transmissible disease, 161
Airborne particles of *M. tuberculosis*, 2
Albumin-based carriers, 128
Alginate-based ATD-nanomedicine, 150
Alginate-based carriers, 126
Antigenic target, 10
Antitubercular drug delivery systems, 144
Antituberculosis drug (ATB) delivery, inhalable polymeric dry powders for
 clinical trials, 100
 drug carriers for pulmonary delivery, 96
 dry powder inhalers

 formulations for, 96
 inhalation delivery devices for, 99
 feasibility of lung as a portal for delivery of, 93
 hybrid nano-in-microparticles, 98
 liposomes, 98
 microparticles, 99
 polymeric nanoparticles, 96
 polymeric powder-based drug development for TB, 101
 pulmonary drug delivery, 92
 solid-lipid nano particles, 98
 therapies, 92
ATD-nanomedicine, 155

B

Bacilli Calmette-Guérin (BCG), 130
Bacterial metabolic pathway, modulation of, 10
BCG. *See* Bacilli Calmette-Guérin (BCG)
Bedaquiline, 231
Biodegradable synthetic polymer-based nanoparticles, 138

C

Calcineurin pathway, 8
Capsule, mycobacterium tuberculosis cellular structure of, 12
 host-pathogen interaction from, 12
 pharmaceutical methodology to target, 14
Carbonaceous nanomaterials-based DNA biosensors
 carbon nanotubes, 211
 graphene derivatives, 208
Carbon nanotubes (CNTBs), 45, 211
Cationic nanoparticle-based TB vaccine delivery, 83
Cerebral TB, 118, 153
Chitosan-base carriers, 124

 nanoparticle TB vaccine delivery, 83
CNTBs. *See* carbon nanotubes (CNTBs)
Cold homogenization method
 emulsification-ultrasonication method, 195
 film-ultrasonication method, 195
 microemulsion technique, 195
 solvent diffusion method, 195
 solvent emulsification evaporation method, 195
 supercritical fluid (SCF) technology, 195
Combination chemotherapy, 117
Conducting airways, mechanical defense of, 15, 16f

Cord factor, 6
CS. *See* Cycloserine (CS)
Cycloserine (CS), 32
Cytokines, role of, 10

D

Delamanid, 235
Dendrimers, 43
 based drug delivery systems for tuberculosis treatment
 Melamine, PEHAM, and PEA dendrimers, 168
 PAMAM dendrimers, 164
 PPI dendrimers, 166
 based TB vaccine delivery system, 85
Directly observed therapy, 38. *See also* First line drugs
DNA structure, 206
DNA TB vaccine, 78
DPI. *See* dry powder inhalers (DPI)
Drug carriers, for pulmonary delivery, 96
Drug regimens, for treatment of tuberculosis, 28
Drug resistance, mechanisms of, 32
Drug-resistant TB, 153

- Drug-resistant tuberculosis, 55
 Dry particle deposition, in lungs, 95f
 Dry powder inhalers (DPI)
 formulations for, 96
 inhalation delivery devices for, 99
- E**
 Emulsification-ultrasonication
 method, 195
 Emulsion-based systems
 microemulsion, 42
 nanoemulsions, 42
 Ethambutol, first line drugs for
 tuberculosis, 30, 162
 Exocytosis, 7
 Extensively drug-resistant tuberculosis
 (XDR TB), 108
- F**
 Feasibility of lung, as portal for
 delivery of ATB, 93
 Film-ultrasonication method, 195
 First line drugs, for tuberculosis
 ethambutol, 30
 isoniazid, 29
 pyrazinamide, 30
 rifampin, 30
 streptomycin, 31
 Formulation and their delivery, 87
- G**
 Gelatin-based carriers, 127
 Generic sec-dependent secretion
 pathway, 10
 Genomics, 64
 Granuloma formation, 22
 Graphene derivatives, 208
 Guar gum-based carriers, 127
- H**
 Host-directed therapies, 238
 Host-directed therapy, for tuberculosis,
 61
 Hot homogenization method, 194
 Hybrid nano-in-microparticles, 98
- I**
 Immune stimulating complexes
 (ISCOMs) as TB vaccine
 delivery system, 86
 Immunology
 adaptive immunity, 21
 granuloma formation, 22
 inflammatory responses, 20
 innate immune system
 bacterial factors that evade these
 innate immune responses, 18
 effector functions of macrophages
 against engulfed mycobacterium
 tuberculosis, 20
 mechanisms of recognition of
 MTB by innate immune system,
 19
 mycobacterial cell wall, 17
 recognition of mycobacterium
 tuberculosis, 17
 of tuberculosis, 15
 Inflammatory responses, 20
 Injectable ATD-nanomedicine, 149
 Innate immune system
 bacterial factors evade innate
 immune responses, 18
 effector functions of macrophages
 against engulfed
 mycobacterium tuberculosis, 20
 mechanisms of recognition of MTB
 by innate immune system, 19
 mycobacterial cell wall, 17
 recognition of mycobacterium
 tuberculosis, 17
 Intradermal route of administration,
 81
 Intramuscular route of administration,
 81
 Intranasal (mucosal, sublingual) route
 of administration, 81
 ISCOMs. *See* immune stimulating
 complexes (ISCOMs)
 Isoniazid, first line drugs for
 tuberculosis, 29, 162
- L**
 Laryngeal TB disease, 2
 Latent TB, 153
 Levofloxacin, 117
 Ligand-appended oral ATD-
 nanomedicine, 148
- Lipid**
 based ATD-nanomedicine
 liposome-based drug delivery
 systems, 151
 microemulsions as potential ATD
 delivery systems, 152
 niosomes-based ATD delivery
 system, 152
 solid lipid nanoparticles-based
 ATD-nanomedicine, 153
 carriers, 197
 nanocarriers, 196
 nanoparticles, 196
- Liposomes (LPS), 42, 98**
 based drug delivery systems, 151
 based TB vaccine delivery, 85
 pulmonary TB and the importance
 of liposomal drugs, 112
 Si-RNA liposomes, 113
 targeting of, 114
 types and uses of, 111
- Lipospheres (LIPs), 43**
 LIPs. *See* lipospheres (LIPs)
 LPS. *See* liposomes (LPS)
- M**
 Macrophage
 apoptosis, 20
 stages of, 9f
 Magnetic beads (MBs), 221
 MBs. *See* magnetic beads (MBs)
 MDR TB. *See* multidrug resistant
 tuberculosis (MDR TB)
 ME. *See* microemulsion (ME)
 Melamine dendrimers, for tuberculosis
 treatment, 168
 Metabolomics, 66
 Metal oxide nanoparticles, 220
 Microemulsion (ME), 42
 as potential ATD delivery systems,
 152
 technique, 195
 Microparticles, 99
 Microspheres, 43
 MTB. *See* Mycobacterium tuberculosis
 (MTB)
 Multidrug-resistant tuberculosis
 (MDR-TB), 108
 bedaquiline, 231
 delamanid, 235
 host-directed therapies, 238
 pretomanid, 235
 Mycobacterial glycolipids, role of, 10
 Mycobacterium tuberculosis (MTB)
 capsule
 cellular structure of, 12
 host-pathogen interaction from,
 12
 pharmaceutical methodology to
 target, 14
 drug regimens, 109
 factors responsible for transmission
 bacteriological factors, 4
 patient-related risk factor, 3

- immunology
 - adaptive immunity, 21
 - granuloma formation, 22
 - inflammatory responses, 20
 - innate immune system, 16
 - of tuberculosis, 15
 - liposomes
 - pulmonary TB and the importance of liposomal drugs, 112
 - Si-RNA liposomes, 113
 - targeting of, 114
 - types and uses of, 111
 - multidrug resistant tuberculosis and extensively drug-resistant tuberculosis, 108
 - nanodelivery systems
 - nanocarriers, types of, 110
 - nanotechnology-based drug delivery system, 110
 - nature of causative agent, 108
 - niosomes
 - advantages of, 115
 - application of, 116
 - definition, 115
 - drug delivery system role in cerebral, drug-resistant, 118
 - treatment of TB, 117
 - types of, 116
 - pathogenesis, 5
 - pulmonary delivery of nanoparticle encapsulated antitubercular drugs, 118
 - survival mechanisms of
 - advantages due to presence of lipid at *cell wall*, 6
 - after stages of macrophage activation, 9
 - eukaryotic like protein kinases in mycobacterial cell, role of, 8
 - inhibition of phagosome-lysosome *fusion*, 8
 - intercellular growth, 7
 - phagocytic cells, function of, 7
 - seizing of calcineurin pathway, 8
 - stage of granuloma, 7
 - uniqueness in cell wall structure, 6
 - sustained delivery systems, 109
 - transmission, 2
 - Mycolic acids, 6
- N**
- Nanocarriers
 - based on natural polymers
 - polypeptide and protein-based carriers, 127
 - polysaccharide-based carriers, 124
 - based on synthetic polymers
 - PLGA-based nanocarriers, 128
 - types of, 110
 - Nanodelivery systems
 - nanocarriers, types of, 110
 - nanotechnology-based drug delivery system, 110
 - Nanoemulsions (NE), 42
 - Nanomedicine, 146
 - Nanomicelles (NMCs), 46
 - Nano/micro particles (NMPs), 43
 - Nanoparticles (NPs)
 - based delivery systems for vaccination against tuberculosis
 - adjuvants, 135
 - tuberculosis vaccines, 130
 - vaccine delivery systems, 136
 - based-DNA biosensors
 - magnetic beads, 221
 - metal oxide nanoparticles, 220
 - noble metal nanoparticles, 213
 - quantum dots, 222
 - based TB vaccine delivery systems, 82
 - miscellaneous
 - carbon nanotubes, 45
 - dendrimers, 43
 - microspheres, 43
 - nanomicelles, 46
 - nano/micro particles, 43
 - nanosuspension, 46
 - polymersomes, 47
 - Nanostructured lipid carrier, based
 - drug delivery systems for tuberculosis treatment
 - cold homogenization method
 - emulsification-ultrasonication method, 195
 - film-ultrasonication method, 195
 - microemulsion technique, 195
 - solvent diffusion method, 195
 - solvent emulsification
 - evaporation method, 195
 - supercritical fluid (SCF) technology, 195
 - hot homogenization method, 194
 - lipid
 - carriers, 197
 - nanocarriers, 196
 - nanoparticles, 196
 - nanostructured lipid carriers, 197
 - solid lipid nanoparticles, 197
 - Nanostructured lipid carriers, 197
 - Nanosuspension (NSP), 46
 - Nanotechnology approach
 - alginate-based ATD-nanomedicine, 150
 - antitubercular drug delivery systems, 144
 - ATD-nanomedicine, 155
 - cerebral TB, drug-resistant TB, and latent TB, 153
 - in conquering anti-TB resistance
 - antituberculosis and mechanism of antituberculosis resistant, 251
 - nanoparticle and its use, 256
 - pathogenesis and its problem in resistant, 249
 - injectable ATD-nanomedicine, 149
 - ligand-appended oral ATD-nanomedicine, 148
 - lipid-based ATD-nanomedicine
 - liposome-based drug delivery systems, 151
 - microemulsions as potential ATD delivery systems, 152
 - niosomes-based ATD delivery system, 152
 - solid lipid nanoparticles-based ATD-nanomedicine, 153
 - nanomedicine, 146
 - oral ATD-nanomedicine, 147
 - potential toxicity of ATD-nanomedicine, 154
 - Nanotechnology-based systems, and administration of drugs against tuberculosis
 - emulsion-based systems
 - microemulsion, 42
 - nanoemulsions, 42
 - nanoparticles, miscellaneous
 - carbon nanotubes, 45
 - dendrimers, 43
 - microspheres, 43
 - nanomicelles, 46
 - nano/micro particles, 43
 - nanosuspension, 46
 - polymersomes, 47
 - solid-lipid forms
 - nanostructured lipid carrier, 42
 - solid-lipid microparticles, 40
 - solid-lipid nanoparticles, 40
 - vesicular drug-delivery systems
 - liposomes, 42
 - lipospheres, 43
 - niosomes, 43

- Nasopharyngeal airways, 15
 Natural killer cells (NK cells), 20
 Natural polymer-based nanoparticles, 137
 NE. *See* nanoemulsions (NE)
 NIOs. *See* niosomes (NIOs)
 Niosomes (NIOs), 43
 advantages of, 115
 application of, 116
 based ATD delivery system, 152
 definition, 115
 drug delivery system role in
 cerebral, drug-resistant, 118
 treatment of TB, 117
 types of, 116
 NK cells. *See* Natural killer cells (NK cells)
 NMCs. *See* nanomicelles (NMCs)
 NMPs. *See* nano/micro particles (NMPs)
 Noble metal nanoparticles, 213
 Nonbiodegradable synthetic polymers, 139
 NPs. *See* nanoparticles (NPs)
 NSP. *See* nanosuspension (NSP)
- O**
 OMICs of tuberculosis, 62
 Oral ATD-nanomedicine, 147
 Oxidants impair ciliary function, 15
- P**
 PAMAM dendrimers, for tuberculosis treatment, 164
 PAMPs. *See* pathogen associated molecular patterns (PAMPs)
 Pathogen associated molecular patterns (PAMPs), 17
 Patient-related risk factor, in MTB
 proximate risk factor, 3
 and socioeconomic status, links between, 3
 urbanization, role of, 4
 Pattern recognition receptors (PRRs), 17
 PBP. *See* penicillin-binding protein (PBP)
 PEA dendrimers, for tuberculosis treatment, 168
 PEHAM dendrimers, for tuberculosis treatment, 168
 Penicillin-binding protein (PBP), 32
 Phagocytosis, 7f
 Phagolysosome, 7
 lysosome fusion, inhibition of, 8
 PLGA-based nanocarriers, 128
 PMDIs. *See* pressurized metered dose inhalers (pMDIs)
 Polymer-based nanoparticles as delivery systems
 nanocarriers based on natural polymers
 polypeptide and protein-based carriers, 127
 polysaccharide-based carriers, 124
 nanocarriers based on synthetic polymers
 PLGA-based nanocarriers, 128
 nanoparticle-based delivery systems for vaccination against tuberculosis
 adjuvants, 135
 tuberculosis vaccines, 130
 vaccine delivery systems, 136
 Polymeric micelle, based drug delivery systems for tuberculosis treatment
 advances of, 182
 amphiphilic block copolymers, 177
 bradykinin and permeability of cells, 180
 corona of, 174
 delivery approaches, 181
 enhanced permeability and retention effect, 178
 free radicals in cell permeability, 180
 permeability and prostaglandin with other factors, 181
 structure of, 174
 Polymeric nanoparticles, 96
 Polymeric/polyester-based nanoparticle TB vaccine delivery system, 84
 Polymeric powder-based drug development for TB, 101
 Polymersomes, 47
 Polypeptide based carriers
 albumin-based carriers, 128
 gelatin-based carriers, 127
 Polysaccharide-based carriers
 Alginate-based carriers, 126
 Chitosan-based carriers, 124
 Guar gum-based carriers, 127
 Polysaccharide-conjugate vaccine, 14
 Postexposure vaccines, 132
 Potential toxicity of ATD-nanomedicine, 154
 PPI dendrimers, for tuberculosis treatment, 166
 Preexposure vaccines, 131
 Pressurized metered dose inhalers (pMDIs), 119
 Pretomanid, 235
 Programmed cell death, 20
 Proteomics, 65
 Proximate risk factor, in MTB
 and socioeconomic status, links between, 3
 urbanization, role of, 4
 PRRs. *See* pattern recognition receptors (PRRs)
 Pulmonary drug delivery, 92
 drug carriers for, 96
 of nanoparticle encapsulated antitubercular drugs, 118
 Pulmonary TB disease, 2
 Pyrazinamide, first line drugs for tuberculosis, 30, 162
- Q**
 QDs. *See* quantum dots (QDs)
 Quantum dots (QDs), 222
- R**
 Reactive nitrogen intermediates (RNI), 20
 Reactive oxygen intermediates (ROI), 20
 Rifampin, first line drugs for tuberculosis, 30, 162
 RNI. *See* Reactive nitrogen intermediates (RNI)
 ROI. *See* Reactive oxygen intermediates (ROI)
- S**
 SCF technology. *See* supercritical fluid (SCF) technology
 Second-line antituberculosis drugs, 31
 SLM. *See* solid-lipid microparticles (SLM)
 Solid-lipid forms
 nanostructured lipid carrier, 42
 solid-lipid microparticles, 40
 solid-lipid nanoparticles, 40
 Solid-lipid microparticles (SLM), 40, 98, 197
 based ATD-nanomedicine, 153
 Solvent diffusion method, 195
 Solvent emulsification evaporation method, 195

- Streptomycin, first line drugs for tuberculosis, 31
- Subcutaneous route of administration, 81
- Supercritical fluid (SCF) technology, 195
- Survival mechanisms of mycobacterium tuberculosis advantages due to presence of lipid at cell wall, 6 after stages of macrophage activation, 9 eukaryotic like protein kinases in mycobacterial cell, role of, 8 inhibition of phagosome-lysosome fusion, 8 intercellular growth, 7 phagocytic cells, function of, 7 seizing of calcineurin pathway, 8 stage of granuloma, 7 uniqueness in cell wall structure, 6
- T**
- TACO. *See* tryptophan aspartate containing coat protein (TACO)
- Therapeutic vaccines, 133
- TLR ligands. *See* Toll-like receptors (TLR) ligands
- Toll-like receptors (TLR) ligands, role of, 10
- Transcriptomics, 64
- Transmission, factors responsible for bacteriological factors, 4 patient-related risk factor, 3
- Tryptophan aspartate containing coat protein (TACO), 8
- TST. *See* tuberculin skin test (TST)
- Tuberculin skin test (TST), 4
- Tuberculosis (TB). *See also* Dendrimers; Mycobacterium tuberculosis; Nanostructured lipid carrier; Polymeric micelle drug regimens for treatment of, 28 ethambutol, 30 first line drugs for, 29 infectious disease, 28 as infectious disease, 37 isoniazid, 29 mechanisms of drug resistance, 32 nanotechnology-based approaches alginate-based ATD-nanomedicine, 150 antitubercular drug delivery systems, 144 ATD-nanomedicine, 155 cerebral TB, drug-resistant TB, and latent TB, 153 injectable ATD-nanomedicine, 149 ligand-appended oral ATD-nanomedicine, 148 lipid-based ATD-nanomedicine, 151 nanomedicine, 146 oral ATD-nanomedicine, 147 potential toxicity of ATD-nanomedicine, 154 pulmonary delivery of ATD-nanomedicine, 148 nanotechnology-based systems and administration of drugs against emulsion-based systems, 42 factors affecting nanoparticles properties, 48 nanoparticles, 43 solid-lipid forms, 40 vesicular drug-delivery systems, 42 pyrazinamide, 30 rifampin, 30 second-line antituberculosis drugs, 31 streptomycin, 31 translational research for therapy against advance therapy, 55 drugs repurposed for, 58 genomics, 64 host-directed therapy for, 61 metabolomics, 66 new drugs for, 56 OMICs of, 62 proteomics, 65 transcriptomics, 64 vaccine delivery systems against adjuvanted subunit TB vaccine, 78 advanced TB vaccine delivery systems, 82 DNA TB vaccine, 78 vaccine administration routes for TB vaccine, 80 whole-cell and live *Mycobacteria* TB vaccine, 80
- U**
- Upper respiratory track, immunology of, 15
- V**
- Vaccine administration routes for TB vaccine intradermal route of administration, 81 intramuscular route of administration, 81 intranasal (mucosal, sublingual) route of administration, 81 subcutaneous route of administration, 81 Vaccine delivery systems against tuberculosis adjuvanted subunit TB vaccine, 78 advanced TB vaccine delivery systems cationic nanoparticle-based TB vaccine delivery, 83 chitosan-based nanoparticle TB vaccine delivery, 83 dendrimer-based TB vaccine delivery system, 85 formulation and their delivery, 87 immune stimulating complexes (ISCOMs) as a TB vaccine delivery system, 86 liposome-based TB vaccine delivery, 85 nanoparticles-based TB vaccine delivery systems, 82 polymeric/polyester-based nanoparticle TB vaccine delivery system, 84 virosomes-based TB vaccine delivery system, 87 virus-like particles (VLPs)-based TB vaccine delivery system, 86 DNA TB vaccine, 78 vaccine administration routes for TB vaccine intradermal route of administration, 81 intramuscular route of administration, 81 intranasal (mucosal, sublingual) route of administration, 81 subcutaneous route of administration, 81 whole-cell and live *Mycobacteria* TB vaccine, 80 Vesicular drug-delivery systems liposomes, 42 lipospheres, 43 niosomes, 43

Viral vectored TB vaccines, 78

Virosomes-based TB vaccine delivery system, 87

Virus-like particles (VLPs)-based TB vaccine delivery system, 86

W

WAX D fraction of lipid, 6

Whole-cell and live *Mycobacteria* TB vaccine, 80

X

XDR TB. *See* extensively drug-resistant tuberculosis (XDR TB)

Nanotechnology Based Approaches for Tuberculosis Treatment

Edited by

Prashant Kesharwani

Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard (A Government-aided Deemed University), New Delhi, India

Nanotechnology Based Approaches for Tuberculosis Treatment discusses multiple nanotechnology-based approaches which may help overcome persisting limitations of conventional and traditional treatment of tuberculosis (TB). A quarter of the world's population is infected with TB, and despite potentially curative pharmacotherapies being available for over 50 years, TB deaths persist, and multidrug-resistant strains of TB are emerging due to prolonged treatment, high pill burden, and low patient compliance. The book summarizes the pathogenesis, biology, immunology, drug regimens and multidrug resistance of tuberculosis followed by various types of nano drugs, their synthesis, formulation, characterization, and applications, along with the most important administration routes. It also explores recent advances and achievements regarding therapeutic efficacy and provides possible future applications in this field. *Nanotechnology Based Approaches for Tuberculosis Treatment* directly addresses translational aspects and clinical perspectives of tuberculosis nanomedicine from a comprehensive and multidisciplinary perspective. It will be a useful resource for investigators, pharmaceutical researchers, innovators, and scientists working on technology advancement in the areas of designing targeted therapies, nano scale imaging systems and diagnostic modalities in tuberculosis. *Nanotechnology Based Approaches for Tuberculosis Treatment* will also cater to the basic needs of students and new researchers in the fields of tuberculosis and nanomedicine.

Key Features

- Addresses the gap between nanomedicine late discovery and early development of tuberculosis therapeutics
- Explores tuberculosis nanomedicine standardization and characterization with newly developed treatment, diagnostic and treatment monitoring modalities
- Covers the field thoroughly from pathogenesis of tuberculosis and multi-drug resistant mycobacterium tuberculosis to treatment approaches using nanotechnology and different nanocarriers




ACADEMIC PRESS

An imprint of Elsevier

elsevier.com/books-and-journals

ISBN 978-0-12-819811-7



9 780128 198117